Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)

Phase 1

Completed

• Conditions: Crohn's Disease
• Interventions: Drug: Alequel

• Registration Number: NCT02185183
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

Oral administration of Alequel, a mixture of proteins derived from the patient's bowel will be tested in patients with inflammatory bowel disease.

Detailed Description

Oral administration of Alequel prepared from patients biopsies will be tested in patients with inflammatory bowel disease to determine its anti inflammatory effect.

Study Timeline

• Status Verified: 2008-01
• Study Start: 2008-01
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Study First Submitted: 2014-04-28
• Study First Submitted QC: 2014-07-06
• Study First Posted: 2014-07-09
• Results First Submitted: 2014-09-07
• Results First Submitted QC: 2014-09-17
• Last Update Submitted: 2014-09-21
• Results First Posted: 2014-09-22
• Last Update Posted: 2014-10-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Crohn's disease

Exclusion Criteria

• Immune suppression

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AlequelTM	Alequel	AlequelTM

Primary Outcome Measures

Name	Time	Method
Number of Participants With Improved in Disease Activity	15 weeks